Augustina Isioma Ikusemoro: Why Plasma and RBC Transfusions Follow Different Compatibility Rules
Augustina Isioma Ikusemoro, Hematology and Transfusion Medicine Specialist at Sharjah Blood Transfusion and Research Center, shared a post on LinkedIn:
“The wrong blood product can turn a life-saving transfusion into a life-threatening mistake.
ABO compatibility is not just laboratory science – it is patient safety.
One of the most misunderstood areas in transfusion medicine is this:
RBC compatibility and plasma compatibility are not the same.
For Red Blood Cells (RBCs):
We avoid giving antigens the patient does not have.
- Group O – universal RBC donor
- Group AB – universal RBC recipient
But for Plasma (FFP):
The rule is reversed.
- Group AB plasma – universal plasma donor
- Group O patients – can receive plasma from all groups
And what happens in emergencies when AB plasma is unavailable for an AB patient?
Clinical judgment matters.
Low-titer Group A plasma may be the preferred alternative.
Low-titer Group O plasma may be used as a last resort.
Group B plasma should generally be avoided.
The key lesson?
Knowing compatibility saves lives.
Because in transfusion medicine:
Right patient. Right product. Right time.
Not all blood products follow the same compatibility rules – and understanding the difference can prevent avoidable transfusion reactions.
Signature of Blood Doki. Educate. Empower. Elevate. Better blood. Better care. Better outcomes.”
Other posts featuring Augustina Isioma Ikusemoro on Hemostasis Today.
-
Aug 22, 2026, 15:53Howard Smith: Publix’s GreenWise Organic Frozen Berries Have E. coli Contamination
-
Aug 22, 2026, 15:13Arthur Allen: Empowering Clinicians to Act
-
Aug 22, 2026, 15:11Bassem M. Mohammed: Factor VIII Structure Analysis Makes the Cover of the Journal of Thrombosis and Haemostasis
-
Aug 22, 2026, 15:03Ahmed Reda: Your Red Blood Cell Can Tell a Story – Not All Anemia Looks the Same
-
Aug 22, 2026, 14:50Marco Meloni: Clinical Management of the Diabetic Foot Attack
-
Aug 22, 2026, 14:41Nico Gagelmann: What is the Future for Patients with Myeloproliferative Neoplasms?
-
Aug 22, 2026, 14:36Arun V J: Leadership Is a Practice, Not a Position – TRAM Masterclass with Judith Chapman
-
Aug 22, 2026, 13:38Jerome Hadjadj: A New Approach to Refractory Immune Thrombocytopenia
-
Aug 22, 2026, 13:25Christopher Robinson: Hematologic Response to Iron Therapy and Stillbirth Risk